Abstract
Erythromelalgia is a characteristic thrombotic complication in patients with the myeloproliferative disorders, essential thrombocythemia and polycythemia vera. In this minireview, which is based on more than 20 years of clinical observations and intervention studies, the clinical manifestations, treatment, and pathogenesis of erythromelalgia are discussed.
MeSH terms
-
Blood Platelets / metabolism
-
Cyclooxygenase Inhibitors / therapeutic use
-
Endothelium, Vascular / pathology
-
Erythromelalgia / drug therapy
-
Erythromelalgia / etiology*
-
Erythromelalgia / pathology
-
Extremities / blood supply
-
Humans
-
Imidazoles / therapeutic use
-
Platelet Activation
-
Polycythemia Vera / complications*
-
Thermography
-
Thrombocythemia, Essential / complications*
Substances
-
Cyclooxygenase Inhibitors
-
Imidazoles
-
dazoxiben